Improving Access to Influenza Testing and Treatment: Is It Time for Over-the-counter Oseltamivir?

Oseltamivir, an antiviral medication that has been used for influenza prophylaxis and treatment since 1999 and now available as a generic drug, is being considered for over-the-counter (OTC) status to allow individuals to access treatment without a prescription. This proposal has engendered controversy. With the rising availability of at-home diagnostic tests and the ever-present threat of an influenza pandemic, it is timely to revisit issues surrounding this controversy. In this commentary, we examine the potential benefits and risks of reclassifying oseltamivir as an OTC drug to enhance access to rapid influenza treatment. Additionally, we explore alternative models to improve oseltamivir accessibility, potentially utilizing rapid influenza testing. As newer drugs to treat influenza are proven safe and effective, they would be subject to similar considerations.

Authors

Institutions

Publication Details

Journal
The Journal of Infectious Diseases
Published
2025-10-15
DOI
https://doi.org/10.1093/infdis/jiaf152
Citations
3
Primary Topic
Influenza Virus Research Studies
Type
article
Field-Weighted Citation Impact
4.06
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Improving Access to Influenza Testing and Treatment: Is It Time for Over-the-counter Oseltamivir?

Kyueun Lee, Janet A. Englund, Andrew T. Pavia
3 citations
The Journal of Infectious Diseases
Influenza Virus Research Studies
4.06
article

Improving Access to Influenza Testing and Treatment: Is It Time for Over-the-counter Oseltamivir?

Kyueun Lee, Janet A. Englund, Andrew T. Pavia
article en
3 citations

Abstract

Oseltamivir, an antiviral medication that has been used for influenza prophylaxis and treatment since 1999 and now available as a generic drug, is being considered for over-the-counter (OTC) status to allow individuals to access treatment without a prescription. This proposal has engendered controversy. With the rising availability of at-home diagnostic tests and the ever-present threat of an influenza pandemic, it is timely to revisit issues surrounding this controversy. In this commentary, we examine the potential benefits and risks of reclassifying oseltamivir as an OTC drug to enhance access to rapid influenza treatment. Additionally, we explore alternative models to improve oseltamivir accessibility, potentially utilizing rapid influenza testing. As newer drugs to treat influenza are proven safe and effective, they would be subject to similar considerations.

The Journal of Infectious DiseasesVol. 232(Supplement_3)
University of Washington (US), University of Utah (US), Spencer Foundation (US), Institute of Translational Health Sciences (US), Seattle Children's Hospital (US)
Openalex Percentile: Top 5%
Influenza Virus Research Studies
4.06
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.